## Duopa
\(\text{(levodopa/carbidopa enteral suspension)}\)

### APPROVAL CRITERIA

Requests for Duopa (carbidopa and levodopa enteral suspension) may be approved if the following criteria are met:

I. Individual has advanced Parkinson’s disease (PD) with complicated motor fluctuations;  
   **AND**

II. Symptoms have not been adequately controlled with optimal medical therapy which includes the following:

   A. Oral levodopa-carbidopa;  **AND**
   
   B. Dopamine agonists;  **AND**
   
   C. One agent from the following classes:
      1. Catechol-0-methyl transferase (COMT) inhibitor;  **OR**

Duopa (carbidopa and levodopa enteral suspension) may **not** be approved for the following:

I. Individual is receiving a nonselective MAO inhibitor (such as phenelzine or tranylcypromine);  **OR**

II. Individuals has a diagnosis of atypical PD or secondary PD.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0274-18
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0274-18